This article was originally published in The Rose Sheet
Executive Summary1-800-Pharmacy has failed to respond to an inquiry by the Electronic Retailing Self-Regulation Program regarding core claims made in Web site advertising for OHT Peptide-3 Anti-Aging System, watchdog group says July 13. Claims at issue include "contains the exact, clinically tested dosage of each ingredient. This potency ensures that OHT Peptide-3 delivers efficacious results"; "results correspond to a restructuring of the tissue"; and "Experience OHT Peptide-3's Safe, Botox-like Effects," according to ERSP. 1-800-Pharmacy must submit substantiation for the core claims in 10 days, ERSP notes, adding failure to respond will result in referral of the case to the Federal Trade Commission...
You may also be interested in...
Compliance Corner: The 10 Best – And 10 Worst – Things You Can Do When FDA Inspects Your Firm (Part 6)
A panel of longtime industry experts offer manufacturers a list of things they should and shouldn’t do when an investigator from the US agency knocks on their facility door. In this sixth installment of a 10-part series, experts David Elder and John McKay address communication between the front room – where investigators do the majority of their work – and the back room, used by company workers to fulfill investigator requests for documents, records and other information.
Mayzent is the first oral treatment specifically indicated for patients with secondary-progressive multiple sclerosis and while it is expected to be a blockbuster, the company tells Scrip that educational programs for physicians are a priority.